New hope for Drug-Resistant epilepsy? early trial tests everolimus
NCT ID NCT07095933
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 21 times
Summary
This pilot study tests whether everolimus, a drug that targets a specific cell pathway, can safely reduce seizures in adults with focal epilepsy that doesn't respond to standard medications. Five participants will take everolimus alongside their usual drugs for 12 weeks. The goal is to see if seizure frequency and severity improve, offering a new option for people with refractory epilepsy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuanwu Hospital, Beijing
RECRUITINGBeijing, Beijing Municipality, 100053, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.